最新ニュース Omeros (NASDAQ:OMER) 株価情報

Omeros

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Omeros Corp

Needham analyst Serge Belanger reiterates Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) from Hold to Hold.

News

Reiteration

Analyst Ratings

OMER

Needham Reiterates Hold on Omerosto Hold

D. Boral Capital analyst Jason Kolbert maintains Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) with a Buy and maintains $36 price target.

Price Target

D. Boral Capital Maintains Buy on Omeros, Maintains $36 Price Target

&nbsp;– Newly Completed Sensitivity Analyses Demonstrate Robustness of Previously Announced Survival Superiority Over External Control in Patients with TA-TMA –
<ul>
<li>Sensitivity analyses support the results of the primary endpoint analysis, with representative sensitivity analyses demonstrating:
<ul>
<li>Narsoplimab-treated patients had an over 2-fold reduction (hazard ratio = 0.42 [95% confidence interval: 0.21, 0.83]) to an over 4-fold reduction (hazard ratio = 0.24 [95% confidence interval: 0.13, 0.47] in risk of mortality</li>
<li>P-values ranging from 0.0124 to &lt; 0.00001</li>
</ul>
</li>
<li>The primary endpoint analysis, previously reported on December 19, 2024, showed an over 3-fold reduction in risk of mortality (hazard ratio = 0.32 [95% confidence interval: 0.23, 0.44]; p &lt; 0.00001) in TA-TMA patients treated with narsoplimab compared to the external control registry TA-TMA patients not treated with narsoplimab</li>
<li>Omeros plans to resubmit to FDA later this quarter the BLA for narsoplimab to become the first approved therapeutic for TA-TMA, a life-threatening complication of hematopoietic stem cell transplantation; MAA submission to European regulators targeted by mid-year</li>
</ul>
Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) today announced statistical sensitivity analysis results related to the primary endpoint analysis for narsoplimab, Omeros' first-in-class monoclonal antibody inhibiting the lectin pathway of complement, in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a life-threatening complication in both adult and pediatric hematopoietic stem cell transplantation. The sensitivity analyses, conducted by an independent statistical group, demonstrate the robustness of the results of the previously reported primary endpoint analysis, with representative hazard ratios ranging from 0.24 (95 percent confidence interval: 0.13, 0.47) to 0.42 (95 percent confidence interval: 0.21, 0.83) and p-values ranging from less than 0.00001 to 0.0124.
The following are representative sensitivity analyses conducted by the independent statistical group:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">1.</td>
<td colspan="3" rowspan="1">Overall survival with only treatment as a factor using Inverse Probability of Treatment Weighting (IPTW):</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">Hazard ratio = 0.40 (95 percent confidence interval: 0.29, 0.54)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">P-value &lt; 0.00001</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">2.</td>
<td colspan="3" rowspan="1">Testing proportional hazards assumptions in a sequence of four models in which patient follow-up is truncated at 100 days, 6 months, 1 year, and 2 years using IPTW:</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">100 days:</td>
<td colspan="1" rowspan="1">Hazard ratio = 0.37 (95 percent confidence interval: 0.25, 0.54)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">P-value &lt; 0.00001</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">6 months:</td>
<td colspan="1" rowspan="1">Hazard ratio = 0.32 (95 percent confidence interval: 0.22, 0.45)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">P-value &lt; 0.00001</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">1 year:</td>
<td colspan="1" rowspan="1">Hazard ratio = 0.30 (95 percent confidence interval: 0.22, 0.42)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">P-value &lt; 0.00001</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2 years:</td>
<td colspan="1" rowspan="1">Hazard ratio = 0.29 (95 percent confidence interval: 0.21, 0.41)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">P-value &lt; 0.00001</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">3.</td>
<td colspan="3" rowspan="1">Overall survival with day zero for the external control registry patients set at the median time between the date of TA-TMA diagnosis and the date of narsoplimab treatment initiation for the patients in the OMS721-TMA-001 pivotal trial using IPTW:</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">Hazard ratio = 0.32 (95 percent confidence interval: 0.23, 0.44)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">P-value &lt; 0.00001</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">4.</td>
<td colspan="3" rowspan="1">Overall survival with and without all specified risk factors (RFs) using 1:1 and 1:2 patient propensity score matching (OMS721-TMA-001 trial patients versus external control registry patients):</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">1:1 with RFs:</td>
<td colspan="1" rowspan="1">Hazard ratio = 0.29 (95 percent confidence interval: 0.14, 0.61)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">P-value = 0.0012</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">1:1 w/out RFs:</td>
<td colspan="1" rowspan="1">Hazard ratio = 0.42 (95 percent confidence interval: 0.21, 0.83)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">P-value = 0.0124</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">1:2 with RFs:</td>
<td colspan="1" rowspan="1">Hazard ratio = 0.24 (95 percent confidence interval: 0.13, 0.47)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">P-value &lt; 0.0001</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">1:2 w/out RFs:</td>
<td colspan="1" rowspan="1">Hazard ratio = 0.40 (95 percent confidence interval: 0.22, 0.72)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">P-value = 0.0024</td>
</tr>
</tbody>
</table>
</figure>
As reported on December 19, 2024, narsoplimab met its primary endpoint, with TA-TMA patients in its OMS721-TMA-001 pivotal trial demonstrating clinically meaningful and statistically significant superiority in overall survival – a hazard ratio of 0.32 (95 percent confidence interval: 0.23 to 0.44) with p-value less than 0.00001 – compared to the TA-TMA registry patients. The hazard ratio of 0.32 indicates that the narsoplimab-treated TA-TMA patients had an over 3-fold reduction in risk of mortality. Across all its clinical trials in various indications to date, narsoplimab has been well tolerated and has shown no safety signal of concern.

Biotech

General

meros Announces Sensitivity Results For Narsoplimab In TA-TMA Patients, Confirming Over 3-Fold Mortality Risk Reduction; Primary Endpoint Met. BLA Resubmission To FDA This Quarter, MAA Submission In Europe By Mid-Year.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Scotiabank analyst Sung Ji Nam initiated coverage on Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Sector Perform rating and announced a price target of $605. Thermo Fisher Scientific shares closed at $524.05 on Friday. <a href="https://www.benzinga.com/quote/TMO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs analyst Allen Chang initiated coverage on Pony AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) with a Buy rating and announced a price target of $19.6. Pony AI shares closed at $13.16 on Friday. See how other analysts view this stock.</li>
<li>Compass Point analyst Dominick Gabriele initiated coverage on NCR Atleos Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NATL#NYSE">NATL</a>) with a Buy rating and announced a price target of $57. NCR Atleos shares closed at $32.33 on Friday. <a href="https://www.benzinga.com/quote/NATL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>D. Boral Capital analyst Jason Kolbert initiated coverage on Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) with a Buy rating and announced a price target of $36. Omeros shares closed at $10.31 on Friday. <a href="https://www.benzinga.com/quote/OMER/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Alliance Global Partners analyst Aaron Grey initiated coverage on Worksport Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKSP#NASDAQ">WKSP</a>) with a Buy rating and announced a price target of $2. Worksport shares closed at $0.8465 on Thursday. <a href="https://www.benzinga.com/quote/WKSP/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying OMER stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="573" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192-1024x573.png" alt="" class="wp-image-704444" style="width:622px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192-1024x573.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192-768x430.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>

Initiation

Markets

Trading Ideas

NATL

PONY

WKSP

This Omeros Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

D. Boral Capital analyst Jason Kolbert initiates coverage on Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) with a Buy rating and announces Price Target of $36.

D. Boral Capital Initiates Coverage On Omeros with Buy Rating, Announces Price Target of $36

<h3>Gainers</h3>
<ul>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares moved upwards by 376.8% to $3.19 during Thursday's pre-market session. The market value of their outstanding shares is at $13.7 million. </li>
<li>Mesoblast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) stock rose 50.2% to $18.4. The company's market cap stands at $2.0 billion. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares increased by 38.56% to $2.12. The market value of their outstanding shares is at $1.7 million. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) stock moved upwards by 35.45% to $1.49. The market value of their outstanding shares is at $76.7 million. </li>
<li>Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) stock rose 33.78% to $9.98. The company's market cap stands at $578.3 million. </li>
<li>Mainz Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) stock rose 26.21% to $4.77. The market value of their outstanding shares is at $10.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) shares fell 35.1% to $0.43 during Thursday's pre-market session. The market value of their outstanding shares is at $5.9 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock decreased by 26.75% to $2.41. The market value of their outstanding shares is at $10.1 million. </li>
<li>Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) stock fell 20.01% to $11.2. The company's market cap stands at $681.5 million. </li>
<li>Marker Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRKR#NASDAQ">MRKR</a>) stock decreased by 17.87% to $3.31. The market value of their outstanding shares is at $29.5 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares fell 13.93% to $3.4. The market value of their outstanding shares is at $3.2 million. </li>
<li>Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) stock fell 12.85% to $390.0. The market value of their outstanding shares is at $100.4 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AEMD

BPTH

ISPC

MESO

MRKR

MYNZ

PLRX

PLRZ

VRTX

12 Health Care Stocks Moving In Thursday's Pre-Market Session

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 100 points on Thursday.
The Dow traded up 0.55% to 42,557.62 while the NASDAQ rose 0.52% to 19,492.93. The S&amp;P 500 also rose, gaining, 0.46% to 5,899.14.
Check This Out: <a href="https://www.benzinga.com/24/12/42582254/top-3-consumer-stocks-you-may-want-to-dump-this-quarter">Top 3 Consumer Stocks You May Want To Dump This Quarter</a>
Leading and Lagging Sectors Utilities shares rose by 1.3% on Thursday.
In trading on Thursday, energy shares fell by 0.8%.
Top Headline
U.S. initial jobless claims declined by 22,000 to 220,000 in the first week of December, compared to market estimates of 230,000.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) shares shot up 39% to $10.38 after the company's Narsoplimab met pivotal trial primary endpoint.</li>
<li>Shares of Trio Petroleum Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPET#NASDAQ">TPET</a>)got a boost, surging 100% to $1.6500 after the company announced it will acquire the oil and gas assets in a heavy oil region of Saskatchewan, Canada for approximately $1.4 million.</li>
<li>Bio-Path Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares were also up, gaining 162% to $1.7501 after the company announced preclinical testing of BP1001-A as a potential treatment for obesity in Type 2 diabetes patients by enhancing insulin sensitivity.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Snow Lake Resources Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITM#NASDAQ">LITM</a>) shares dropped 63% to $0.3101 as the company reported the pricing of public offering.</li>
<li>Shares of Lamb Weston Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) were down 23% to $60.49 after the company reported worse-than-expected Q2 earnings and lowered FY25 outlook.</li>
<li>Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) was down, falling 17% to $86.66. Micron posted better-than-expected earnings for its first quarter, while sales missed expectations. The company said it sees second-quarter revenue of $7.9 billion, plus or minus $200 million, versus estimates of $9 billion. The company expects second-quarter adjusted earnings of $1.43 per share, plus or minus 10 cents per share, versus estimates of $1.92 per share.</li>
</ul>
Commodities In commodity news, oil traded down 1% to $69.89 while gold traded down 1.5% at $2,614.90.
Silver traded down 4% to $29.540 on Thursday, while copper fell 1.8% to $4.0835.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 dipped 1.51%, Germany's DAX fell 1.35% and France's CAC 40 declined 1.22%. Spain's IBEX 35 Index fell 1.53%, while London's FTSE 100 fell 1.14%.
Asia Pacific Markets
Asian markets closed lower on Thursday, with Japan's Nikkei 225 falling 0.69%, Hong Kong's Hang Seng Index falling 0.56%, China's Shanghai Composite Index declining 0.36% and India's BSE Sensex falling 1.20%.
Economics
<ul>
<li>The Philadelphia Fed Manufacturing Index dipped to -16.4 in December compared to -5.5 in November and down from market expectations of 3.</li>
<li>The U.S. economy grew by an annualized rate of 3.1% in the third quarter compared to 2.8% in the second estimate and up from 3% in the previous quarter.</li>
<li>U.S. existing home sales gained by 4.8% from the previous month to an annualized rate of 4.15 million in November.</li>
<li>U.S. initial jobless claims declined by 22,000 to 220,000 in the first week of December, compared to market estimates of 230,000.</li>
<li>The Kansas City Fed's Manufacturing Production Index declined by one point to a reading of -5 in December.</li>
<li>U.S. natural-gas supplies fell 125 billion cubic feet during the week ending Dec. 13.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42591599/att-to-rally-more-than-33-here-are-10-top-analyst-forecasts-for-thursday">AT&amp;T To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Thursday</a></li>
</ul>

Equities

Eurozone

Commodities

LITM

TPET

Nasdaq Jumps 100 Points, US Initial Jobless Claims Decline

On Thursday, Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) announced that an independent statistical group has completed the primary statistical analysis agreed with the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42587568/omeros-narsoplimab-meets-its-pivotal-trial-primary-endpoint-statistical-analysis-shows-survival-su" rel="noreferrer noopener">FDA for narsoplimab</a>.
Omeros is a first-in-class monoclonal antibody that inhibits the lectin pathway of complement in hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
TA-TMA is a complication in adult and pediatric hematopoietic stem cell transplantation (HSCT).
The analysis compared overall survival in the 28 TA-TMA patients in OMS721-TMA-001, Omeros&#8217; previously conducted pivotal trial for narsoplimab in TA-TMA, to that of more than 100 similarly high-risk TA-TMA patients in an external control registry of HSCT patients who did not receive narsoplimab treatment.
Narsoplimab met its primary endpoint, with OMS721-TMA-001 patients demonstrating clinically meaningful and statistically significant superiority in overall survival – a hazard ratio of 0.32 compared to the TA-TMA registry patients.
Late last month, Omeros announced that it had received FDA&#8217;s recommendations on the statistical analysis plan (SAP) for the primary analysis comparing overall survival from the time of first dosing in the 28 narsoplimab-treated TA-TMA patients in the pivotal trial OMS721-TMA-001 to overall survival, adjusted for immortal time bias, of the more than 100 TA-TMA patients in the external control registry, none of whom received narsoplimab.
To date, narsoplimab has been well tolerated and has shown no safety signal of concern across all its clinical trials in various indications.
Given the primary analysis results, we will resubmit the narsoplimab BLA for TA-TMA as quickly as possible, followed by our planned submission of the corresponding European marketing authorization application in the second quarter of 2025.
Additional sensitivity and other analyses are pending and should be available over the next few weeks.
Price Action: OMER stock is up 54.8% at $11.55&nbsp;at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42597812/soho-house-jumps-over-50-on-receiving-acquisition-offer-with-83-premium" target="_blank" rel="noreferrer noopener">Soho House Jumps On Receiving Acquisition Offer With 83% Premium</a></li>
</ul>

Health Care

Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges

U.S. stocks traded higher midway through trading, with the S&amp;P 500 gaining around 0.4% on Thursday.
The Dow traded up 0.39% to 42,493.51 while the NASDAQ rose 0.39% to 19,468.70. The S&amp;P 500 also rose, gaining, 0.38% to 5,894.42.
Check This Out: <a href="https://www.benzinga.com/24/12/42582254/top-3-consumer-stocks-you-may-want-to-dump-this-quarter">Top 3 Consumer Stocks You May Want To Dump This Quarter</a>
Leading and Lagging Sectors Utilities shares rose by 1.1% on Thursday.
In trading on Thursday, health care shares fell by 0.9%.
Top Headline
The U.S. economy grew by an annualized rate of 3.1% in the third quarter compared to 2.8% in the second estimate and up from 3% in the previous quarter.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) shares shot up 50% to $11.22 after the company's Narsoplimab met pivotal trial primary endpoint.</li>
<li>Shares of Trio Petroleum Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPET#NASDAQ">TPET</a>)got a boost, surging 180% to $2.30 after the company announced it will acquire the oil and gas assets in a heavy oil region of Saskatchewan, Canada for approximately $1.4 million.</li>
<li>Bio-Path Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares were also up, gaining 135% to $1.5700 after the company announced preclinical testing of BP1001-A as a potential treatment for obesity in Type 2 diabetes patients by enhancing insulin sensitivity.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Snow Lake Resources Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITM#NASDAQ">LITM</a>) shares dropped 59% to $0.3313 as the company reported the pricing of public offering.</li>
<li>Shares of Lamb Weston Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) were down 23% to $60.43 after the company reported worse-than-expected Q2 earnings and lowered FY25 outlook.</li>
<li>Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) was down, falling 17% to $86.16. Micron posted better-than-expected earnings for its first quarter, while sales missed expectations. The company said it sees second-quarter revenue of $7.9 billion, plus or minus $200 million, versus estimates of $9 billion. The company expects second-quarter adjusted earnings of $1.43 per share, plus or minus 10 cents per share, versus estimates of $1.92 per share.</li>
</ul>
Commodities In commodity news, oil traded down 0.7% to $70.10 while gold traded down 1.7% at $2,608.00.
Silver traded down 4.8% to $29.275 on Thursday, while copper fell 2% to $4.0760.
Euro zone
European shares were lower today. The eurozone's STOXX 600 dipped 1.51%, Germany's DAX fell 1.35% and France's CAC 40 declined 1.22%. Spain's IBEX 35 Index fell 1.53%, while London's FTSE 100 fell 1.14%.
Asia Pacific Markets
Asian markets closed lower on Thursday, with Japan's Nikkei 225 falling 0.69%, Hong Kong's Hang Seng Index falling 0.56%, China's Shanghai Composite Index declining 0.36% and India's BSE Sensex falling 1.20%.
Economics
<ul>
<li>The Philadelphia Fed Manufacturing Index dipped to -16.4 in December compared to -5.5 in November and down from market expectations of 3.</li>
<li>The U.S. economy grew by an annualized rate of 3.1% in the third quarter compared to 2.8% in the second estimate and up from 3% in the previous quarter.</li>
<li>U.S. existing home sales gained by 4.8% from the previous month to an annualized rate of 4.15 million in November.</li>
<li>U.S. initial jobless claims declined by 22,000 to 220,000 in the first week of December, compared to market estimates of 230,000.</li>
<li>The Kansas City Fed's Manufacturing Production Index declined by one point to a reading of -5 in December.</li>
<li>U.S. natural-gas supplies fell 125 billion cubic feet during the week ending Dec. 13.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42591599/att-to-rally-more-than-33-here-are-10-top-analyst-forecasts-for-thursday">AT&amp;T To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Thursday</a></li>
</ul>

Intraday Update

Gold Falls Sharply, Lamb Weston Shares Plunge

U.S. stocks were higher, with the Dow Jones index gaining over 150 points on Thursday.
Shares of Accenture plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) rose sharply in today's session after the company reported better-than-expected first-quarter financial results and raised FY25 <a href="https://www.benzinga.com/24/12/42586612/accenture-delivers-q1-revenue-growth-bolstered-by-consulting-and-managed-services">revenue growth outlook</a>.
On Thursday, Accenture reported first-quarter fiscal 2025 sales of $17.69 billion compared with the analyst consensus estimate of $17.12 billion, up 9% year-over-year in U.S. dollars and 5% in local currency.
Accenture shares jumped 7% to $372.09 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) shares jumped 68% to $12.55 after the company's Narsoplimab met pivotal trial primary endpoint.</li>
<li>Soho House &amp; Co Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHCO#NASDAQ">SHCO</a>) gained 54% to $7.57 after the company received a $9.00 per share acquisition offer from a consortium backed by Executive Chairman Ron Burkle and Yucaipa. The board has formed a special committee to evaluate the proposal.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) rose 35% to $16.55. On Wednesday, the FDA approved Mesoblast's Ryoncil (remestemcel-L) as the first mesenchymal stromal cell (MSC) therapy in the U.S.</li>
<li>Microvast Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) gained 21.7% to $1.3990.</li>
<li>Sable Offshore Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>) surged 20.3% to $23.63.</li>
<li>Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) gained 17.8% to $14.09 after the Phase IIb Prasinezumab study showed potential in early Parkinson&#8217;s disease.</li>
<li>Darden Restaurants, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) rose 14.3% to $182.79 after the company reported better-than-expected second-quarter EPS and issued better-than-expected FY25 revenue outlook.</li>
<li>Innodata Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOD#NASDAQ">INOD</a>) gained 14.2% to $39.09. Wedbush analyst Daniel Ives initiated coverage on Innodata with an Outperform rating and announced a price target of $48.</li>
<li>Valneva SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALN#NASDAQ">VALN</a>) gained 10.1% to $4.16. Valneva expanded Chikungunya vaccine access in Asia through partnership with Serum Institute.</li>
<li>Tripadvisor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIP#NASDAQ">TRIP</a>) rose 8.8% to $14.10. Tripadvisor and Liberty TripAdvisor announced a planned merger.</li>
<li>Nordstrom, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) shares gained 4.8% to $23.98.</li>
<li>CarMax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMX#NYSE">KMX</a>) shares rose 4.5% to $85.08 after the company reported better-than-expected quarterly earnings and sales.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42591599/att-to-rally-more-than-33-here-are-10-top-analyst-forecasts-for-thursday">AT&amp;T To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Thursday</a></li>
</ul>

INOD

MVST

PRTA

SHCO

TRIP

VALN

Accenture Posts Upbeat Results, Joins Darden Restaurants, CarMax And Other Big Stocks Moving Higher On Thursday

WIIM

Omeros shares are trading higher after the company announced that narsoplimab met its primary trial endpoint and will resubmit  its narsoplimab Biologics License Application to the FDA.

Omeros' Narsoplimab Met Pivotal Trial Primary Endpoint; Given These Results, Omeros Will Resubmit To FDA As Soon As Possible Its Narsoplimab Biologics License Application For TA-TMA

Omeros Corporation Presents Phase 2 Zaltenibart Data At ASH Meeting, Supporting Dose Selection For Upcoming Phase 3 Clinical Trials In Paroxysmal Nocturnal Hemoglobinuria, With Enrollment Set For Early 2025

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said United Parcel Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) has &#8220;screwed up a lot of holiday seasons.&#8221; He prefers FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) over UPS.
On Oct. 24, United Parcel Service reported better-than-expected third-quarter financial results.
It's time to take profits in Omeros Corporation (NASDAQ:<a href="https://www.benzinga.com/quote/OMER/earnings"> OMER</a>), Cramer said. 
On Nov. 13, Omeros reported better-than-expected third-quarter earnings results.
When asked about Lockheed Martin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), he said, &#8220;I would not touch this thing until it broke 500. But it's run by Jim Taiclet [CEO of Lockheed Martin], and he's really fabulous.&#8221;
On Oct. 22, the company reported net sales growth of 1.3% year-over-year to $17.104 billion, missing the consensus of $17.351 billion. Adjusted EPS of $6.84, up from $6.77 in the prior year, topped the consensus of $6.50.
&#8220;I actually think these stocks have over-heated, and I am worried about a strong unemployment number on Friday,&#8221; Cramer said when asked about Archer Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>).
On Nov. 7, Archer Aviation reported better-than-expected third-quarter earnings results.
The &#8220;Mad Money&#8221; host recommended taking a pass on AstraZeneca PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>). &#8220;There's just been a series of disappointments. I don't know what to make of it,&#8221; he added.
On Nov. 12, AstraZeneca reported third-quarter sales of $13.57 billion, up 18% year over year (+21% at constant currency), beating the consensus of $13.09 billion. The company's adjusted EPADS reached $1.04, beating the consensus of $1.03. The adjusted EPS was $2.08 (1 ADR = 2 Common Shares).
Price Action:
<ul>
<li>Lockheed Martin Corporation shares fell 1.1% to settle at $520.34 on Monday.</li>
<li>UPS shares fell 1.3% to close at $134.02.</li>
<li>Omeros shares gained 5.3% to close at $11.95 on Monday.</li>
<li>Archer Aviation shares dipped 23.7% to close at $7.30.</li>
<li>AstraZeneca shares fell 0.9% to settle at $67.04 on Monday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42267284/this-analyst-with-85-accuracy-rate-sees-more-than-8-upside-in-crowdstrike-here-are-5-stock-picks-for-november-from-wall-streets-most-accurate-analysts">This Analyst With 85% Accuracy Rate Sees More Than 8% Upside In CrowdStrike &#8211; Here Are 5 Stock Picks For November From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>
Image: Shutterstock

ACHR

Jim Cramer Prefers FedEx Over This Delivery Giant That 'Screwed Up A Lot Of Holiday Seasons'

U.S. stocks were mixed, with the Dow Jones index gaining more than 150 points on Friday.
Shares of Natural Grocers by Vitamin Cottage, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVC#NYSE">NGVC</a>) rose sharply during Friday's session <a href="https://www.benzinga.com/quote/NGVC/earnings">following quarterly results.</a>
Natural Grocers reported quarterly earnings of 39 cents per share, representing a 50% increase over earnings of 26 cents per share from the same period last year. The company reported $322.66 million in sales this quarter.
Natural Grocers by Vitamin Cottage shares jumped 15.3% to $41.78 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Replimune Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) shares jumped 41.5% to $15.64 after the company on Thursday announced it received breakthrough therapy designation status for RP1 and will submit an RP1 biologics license application to the FDA under an accelerated approval pathway.</li>
<li>Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) shares surged 26.4% to $9.75.</li>
<li>D-Wave Quantum Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) jumped 20.6% to $2.3750 after the company issued expectations for quarter-over-quarter fourth-quarter revenue growth.</li>
<li>Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) gained 18.8% to $2.4000.</li>
<li>Elastic N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) gained 16.6% to $109.82 after the company reported better-than-expected second-quarter financial results and issued FY25 guidance above estimates.</li>
<li>Matthews International Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MATW#NASDAQ">MATW</a>) surged 16.6% to $29.74 following upbeat earnings.</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) rose 16.2% to $7.48.</li>
<li>Viasat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSAT#NASDAQ">VSAT</a>) gained 14.3% to $9.52.</li>
<li>Protagonist Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTGX#NASDAQ">PTGX</a>) jumped 12.3% to $46.81.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) gained 10.7% to $32.90.</li>
<li>SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) shares rose 10.66% to $7.72.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) shares jumped 9.1% to $1.2000</li>
<li>Atkore Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATKR#NYSE">ATKR</a>) gained 8.6% to $92.44. </li>
<li>The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) jumped 6% to $23.35 following upbeat earnings.</li>
<li>Carpenter Technology Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRS#NYSE">CRS</a>) gained 5.3% to $190.29 JP Morgan analyst Bennett Moore initiated coverage on Carpenter Tech with an Overweight rating and announced a price target of $220.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

ATKR

ESTC

MATW

NGVC

NVTS

PSNY

PTGX

QBTS

REPL

SMCI

SOUN

VSAT

WOLF

Natural Grocers By Vitamin Cottage, Elastic, Matthews International, Gap And Other Big Stocks Moving Higher On Friday

U.S. stock futures were mixed this morning, with the Dow futures falling more than 100 points on Monday.
Shares of Neurogene Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) fell sharply in today's pre-market trading after the company announced it brought its high-dose gene therapy trial to a halt after a serious adverse event in a Rett <a href="https://www.benzinga.com/quote/NGNE">syndrome patient</a>.
Neurogene shares declined 37.7% to $21.50 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Rezolve AI Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) shares tumbled 16.1% to $2.29 in pre-market trading after dipping over 20% on Friday.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) shares dipped 12.3% to $4.43 in pre-market trading after gaining around 9% on Friday. Kingsoft Cloud will release its unaudited financial results for the third quarter before the opening bell on Nov. 19.</li>
<li>Luminar Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAZR#NASDAQ">LAZR</a>) tumbled 9.3% to $0.8890 in today's pre-market trading after declining around 5% on Friday.</li>
<li>Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) shares fell 7% to $6.28 in pre-market trading.</li>
<li>CompoSecure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPO#NASDAQ">CMPO</a>) shares declined 5.9% to $13.00 in pre-market trading.</li>
<li>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) shares fell 5.4% to $266.21 in pre-market trading following a 4% decline on Friday.</li>
<li>Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) shares fell 5% to $11.80 in pre-market trading after jumping 21% on Friday.</li>
<li>ProQR Therapeutics N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) shares fell 4% to $3.67 in pre-market trading.</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares fell 2.4% to $138.51 in pre-market trading after declining more than 3% on Friday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42024062/how-to-earn-500-a-month-from-apple-stock">How To Earn $500 A Month From Apple Stock</a></li>
</ul>

Pre-Market Outlook

AMAT

AMGN

CMPO

LAZR

LUNR

NGNE

NVDA

PRQR

RZLV

Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Omeros shares are trading higher after the company reported better-than-expected Q3 EPS results. Also, Rodman & Renshaw initiated coverage on the stock with a Buy rating and announced a $9 price target.

Cantor Fitzgerald analyst Olivia Brayer reiterates Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) with a Neutral.

Cantor Fitzgerald Reiterates Neutral on Omeros

Rodman &amp; Renshaw analyst Brandon Folkes initiates coverage on Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) with a Buy rating and announces Price Target of $9.

Rodman & Renshaw Initiates Coverage On Omeros with Buy Rating, Announces Price Target of $9

Omeros Q3 2024 - Updates On OMIDRIA And Narsoplimab Lead To Liquidity Concerns

Omeros (OMER) announced an update on its progress toward planned resubmission of its biologics license application, or BLA, for narsoplimab, the co...

Omeros provides update on narsoplimab BLA resubmission

Omeros surges 22% on clarity for BLA resubmission for narsoplimab

Omeros Corporation: Investment Opportunity Finely Poised As The Market Waits For Key Updates

Latest data shows the largest indicative borrow rate increases among liquid option names include: FuelCell (FCEL) 34.51% +1.31, Reviva Pharmaceutic...

Largest borrow rate increases among liquid names

Omeros (OMER) announced that an independent statistical group has completed the primary statistical analysis agreed with the FDA for narsoplimab, O...

Omeros announces narsoplimab trial meets primary endpoint

Omeros jumps as lead drug succeeds in pivotal trial for blood transplant patients

D. Boral Capital initiated coverage of Omeros (OMER) with a Buy rating and $36 price target With Narsoplimab now poised for U.S. approval, followed...

Omeros initiated with a Buy at D. Boral Capital

Omeros (OMER) announced statistical sensitivity analysis results related to the primary endpoint analysis for narsoplimab, Omeros' monoclonal antib...

Omeros announces update on statistical analysis of narsoplimab primary endpoint

Needham analyst Serge Belanger maintained a Hold rating on Omeros (OMER – Research Report) today. The company's shares closed yesterday at $9.18. B...

Needham Remains a Hold on Omeros (OMER)

CMRX

FCEL

GRRR

RVPH

SOXS

TARA

Press Releases

Omeros Corporation Reports Second Quarter 2024 Financial Results

FDA Grants Rare Pediatric Disease Designation to Omeros' MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024

Omeros Corporation Reports Third Quarter 2024 Financial Results

Omeros Corporation Provides Update on Progress Toward BLA Resubmission

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting

Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

Comments

Omeros

ニュース

最新ニュース Omeros (NASDAQ:OMER) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル